Skip to main content

Table 5 Comparison of CHEK2 mutation frequency in patients with colorectal cancer and controls

From: Selected aspects of inherited susceptibility to prostate cancer and tumours of different site of origin

Mutation Group Number of carriers/number of tested OR 95% CI p
   (frequency, %)    
  controls 58/5496 (1.1) 1.0   
Protein truncating mutation*      
  unselected cases 11/1058 (1.0) 1.0 0.5–1.8 0.9
  familial cases 2/110 (1.8) 1.7 0.4–7.2 0.44
I157T controls 264/5496 (4.8) 1.0   
  unselected cases 77/1085 (6.6) 1.5 1.2–2.0 0.002
  familial cases 11/110 (10) 2.2 1.2–4.1 0.01
  1. CI – confidence interval; OR – odds ratio; p – p-value
  2. *one of the three truncating mutations (del5395, 1100delC, IVS2+1G>A)